New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.